What it sells
B2B E-commerce & Fintech platform for Pharmacies & Hospitals in Africa
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharmacy owners and hospital procurement staff in Nigeria/Africa; insurers/HMOs for the benefits-manager product.
Trigger: what makes them buy now?
Cash tied up in pharmacy stock and risk of cash-flow crunch; need for counterfeit-proof supply without visiting markets or dealing with many sales reps.
Workflow: what inputs become what output?
Request inventory finance in the Remedial app, get approval within 24 working hours, buy stock on the Remedial Store with a Pay Later option, receive stock within 24 hours, pay as you dispense.
Economics: what it saves and how it charges
UnverifiedSells 5000+ products (branded, generic, specialty medicines, consumables, small devices) sourced direct from manufacturers/vetted distributors plus inventory financing ("pay ONLY for what you dispense"); revenue likely product margin plus credit fees (fee terms not published).
Distribution: how it reaches customers
Mobile app (QR code to app store) plus website sign-up; six product modules (Store, Rx, BNPL, Benefits Manager, Intelligence, Market Access) cross-sold to the same providers.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.